Michael Foley
27Patents
8h-index
92Co-inventors
78Inventor score
Filing activity: Jun 29, 1992 → Nov 8, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6693125B2 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | Human Necessities | 65 | Expired |
| US7230004B2 | Cyclopamine analogues and methods of use thereof | Human Necessities | 55 | Expired |
| US8080553B2 | Methods and reagents for the treatment of immunoinflammatory disorders | Human Necessities | 54 | Active |
| US6569853B1 | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders | Human Necessities | 48 | Expired |
| US7407967B2 | Cyclopamine analogues and methods of use thereof | Human Necessities | 36 | Active |
| US7875628B2 | Cyclopamine analogues and methods of use thereof | Human Necessities | 30 | Active |
| US8236956B2 | Cyclopamine analogues and methods of use thereof | Human Necessities | 20 | Active |
| US6846816B2 | Combinations of drugs for the treatment of neoplastic disorders | Human Necessities | 10 | Expired |
| US7851637B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | Chemistry; Metallurgy | 8 | Expired |
| US11203613B2 | Peptidomimetic proteasome inhibitors | Emerging Cross-Sectional Technologies | 4 | Active |
| US5252560A | Cyclic imide derivatives, compositions and use | Human Necessities | 4 | Expired |
| US7253155B2 | Combinations for the treatment of immunoinflammatory disorders | Human Necessities | 4 | Expired |
| US8349832B2 | Compounds and compositions for treating cancer | Chemistry; Metallurgy | 3 | Active |
| US7148216B2 | Combinations of drugs for the treatment of neoplastic disorders | Human Necessities | 3 | Expired |
| US6448443B1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | Emerging Cross-Sectional Technologies | 2 | Expired |
| US8318737B2 | Compounds and compositions for treating cancer | Chemistry; Metallurgy | 2 | Active |
| US11732005B2 | Peptidomimetic proteasome inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US7109377B2 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | Emerging Cross-Sectional Technologies | 1 | Expired |
| US7915265B2 | Combinations for the treatment of immunoinflammatory disorders | Human Necessities | 0 | Active |
| US11142588B2 | Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer | Physics | 0 | Active |
| US10538596B2 | CXCR4 binding molecules and methods of use thereof | Physics | 0 | Active |
| US11192893B2 | Pyrazoloquinazolinone antitumor agents | Human Necessities | 0 | Active |
| US10357554B2 | AMA-1 epitopes, antibodies, compositions, and methods of making and using the same | Emerging Cross-Sectional Technologies | 0 | Active |
| US11192889B2 | Tetrahydronaphthyridinepentanamide integrin antagonists | Human Necessities | 0 | Active |
| US11834515B2 | Macrocyclic compounds as proteasome inhibitors | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.